Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q49A17

UPID:
GLTL6_HUMAN

ALTERNATIVE NAMES:
Polypeptide GalNAc transferase 17; Protein-UDP acetylgalactosaminyltransferase 17; Putative polypeptide N-acetylgalactosaminyltransferase 17; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 17

ALTERNATIVE UPACC:
Q49A17; Q2L4S6

BACKGROUND:
The enzyme Polypeptide N-acetylgalactosaminyltransferase-like 6, with aliases such as UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 17, is integral to the initiation of O-linked oligosaccharide biosynthesis. This process is essential for the modification of proteins through the attachment of N-acetyl-D-galactosamine to serine or threonine residues, impacting protein function and stability.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Polypeptide N-acetylgalactosaminyltransferase-like 6 offers a pathway to innovative therapeutic approaches. Its key role in protein modification underscores its potential as a target for drug discovery, aiming to manipulate this process for therapeutic benefit.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.